Apr 29 |
AstraZeneca Says Enhertu Phase 3 Trial Shows 'Statistically Significant' Progression-Free Breast Cancer Survival Improvement
|
Apr 29 |
AstraZeneca's Enhertu buoyed by progression-free survival data in breast cancer
|
Apr 29 |
AstraZeneca, Daiichi look to broaden Enhertu use again with new study data
|
Apr 29 |
ENHERTU® (fam-trastuzumab deruxtecan-nxki) improved PFS in HER2-low and ultralow
|
Apr 29 |
Will Earnings Cheer Continue To Buoy Markets? Apple, Amazon, Pfizer, Coinbase Lead Flurry Of Q1 Reports This Week
|
Apr 28 |
J&J, Roche, AstraZeneca poised to have highest orphan drug sales by end of decade
|
Apr 27 |
AstraZeneca: A Triple Shot Of Income, Growth, And Value
|
Apr 27 |
AstraZeneca PLC (LON:AZN) Beat Earnings, And Analysts Have Been Reviewing Their Forecasts
|
Apr 26 |
Pharma Stock Roundup: MRK, SNY, AZN, NVS' Q1 Results, Pipeline & Regulatory Updates
|
Apr 26 |
AstraZeneca: Strong In A Weak Market
|